MIN AMY GUO v. NOVARTIS PHARMACEUTICALS CORPORATION (L-1486-14, MORRIS COUNTY AND STATEWIDE)

CourtNew Jersey Superior Court Appellate Division
DecidedJuly 25, 2022
DocketA-5652-18
StatusUnpublished

This text of MIN AMY GUO v. NOVARTIS PHARMACEUTICALS CORPORATION (L-1486-14, MORRIS COUNTY AND STATEWIDE) (MIN AMY GUO v. NOVARTIS PHARMACEUTICALS CORPORATION (L-1486-14, MORRIS COUNTY AND STATEWIDE)) is published on Counsel Stack Legal Research, covering New Jersey Superior Court Appellate Division primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
MIN AMY GUO v. NOVARTIS PHARMACEUTICALS CORPORATION (L-1486-14, MORRIS COUNTY AND STATEWIDE), (N.J. Ct. App. 2022).

Opinion

NOT FOR PUBLICATION WITHOUT THE APPROVAL OF THE APPELLATE DIVISION This opinion shall not "constitute precedent or be binding upon any court ." Although it is posted on the internet, this opinion is binding only on the parties in the case and its use in other cases is limited. R. 1:36-3.

SUPERIOR COURT OF NEW JERSEY APPELLATE DIVISION DOCKET NO. A-5652-18

MIN AMY GUO,

Plaintiff-Respondent/ Cross-Appellant,

v.

NOVARTIS PHARMACEUTICALS CORPORATION,

Defendant-Appellant/ Cross-Respondent. ______________________________

Argued February 3, 2022 – Decided July 25, 2022

Before Judges Haas, Mawla, and Mitterhoff.

On appeal from the Superior Court of New Jersey, Law Division, Morris County, Docket No. L-1486-14.

John B. McCusker argued the cause for appellant/cross- respondent (McCusker, Anselmi, Rosen & Carvelli, PC, and Porzio, Bromberg & Newman, PC, attorneys; John B. McCusker, Patricia Prezioso and Patrice LeTourneau, on the briefs).

James K. Webber argued the cause for respondent/cross-appellant (Webber McGill LLC, and Richard J. Murray, attorneys; James K. Webber, Douglas J. McGill, and Richard J. Murray, on the briefs).

PER CURIAM

Defendant Novartis Pharmaceuticals Corporation appeals from an August

27, 2019 judgment following a jury verdict in plaintiff Min Amy Guo's favor

pursuant to the Conscientious Employee Protection Act (CEPA), N.J.S.A.

34:19-1 to -14, and awarding her counsel fees. Plaintiff cross-appeals from the

same judgment following the jury's verdict in defendant's favor on its unjust

enrichment counterclaim and she challenges the counsel fees and the no-cause

verdict on punitive damages. We affirm both the appeal and the cross-appeal.

We discern the following facts from the record. Plaintiff began working

for defendant in 2008 as senior director of a new health economics outcome

research (HEOR) department within its oncology division. The department was

tasked with conducting research regarding the economic efficacy of treatment

plans and pharmaceuticals. Over the following several years, plaintiff received

positive performance reviews and earned a promotion to executive director and

salary increase in March 2012. By the time of her termination, she earned an

annual salary of $223,678, as well as cash and stock incentive awards through

defendant's annual incentive plan (AIP) and stock incentive plan (SIP), albeit

A-5652-18 2 subject to claw-back in the event of misconduct pursuant to the rules of each

respective plan. In the event of an employee's noncompliance with the law, the

company's code of conduct, or any provision of the company guidelines, the AIP

explicitly set forth avenues for recovery of any incentives already paid to the

employee. The SIP likewise required a participant's adherence to the same

company policies, including the code of conduct, under the same terms.

During plaintiff's employment, as part of its settlement of a lawsuit

brought by the U.S. Department of Justice alleging violations of the False

Claims Act (FCA), 31 U.S.C. § 3729 to -33, and Anti-Kickback Statute (AKS),

42 U.S.C. § 1320a-7b(b), defendant entered into a corporate integrity agreement

(CIA) in 2010, requiring that it implement and adhere to policies and procedures

to ensure its compliance with federal law, including the FCA and AKS.

Consistent with those policies, defendant provided plaintiff training regarding

compliance with the CIA and, by extension, the AKS. Plaintiff's understan ding

from that training, as pertinent here, was that the company could violate the

AKS by paying a distributor for a study of negligible scientific value as a

kickback for purchasing and distributing its product. In that connection,

defendant does not sell any of its products directly to the general public; rather,

A-5652-18 3 it sells them to firms such as McKesson Corporation (McKesson), which in turn

sells them to pharmacies.

In June 2012, while approval for a new indication to treat breast cancer

for Afinitor remained pending, Christi Shaw, head of defendant's oncology

division, met with Grant Bogle, a senior marketing executive at McKesson, to

discuss the drug's launch. Shaw discussed with Bogle the possibility that

McKesson might perform an HEOR study of Afinitor to support the launch.

Early the following month, Greg Grabavoy, head of defendant's Oncology

Scientific Operations – Managed Markets (OSOMM) group, sent an email

message to Shaw apprising her of a proposed study from McKesson, at a cost to

defendant of $248,500, that would examine McKesson's doctors' existing off-

label use of Afinitor to treat their breast cancer patients. He described the

proposal as a "customer engagement project" that offered a "very quick

turnaround time prior to launch" and suggested a telephone conference the

following week to "expedite approval/funding." Despite the HEOR group's

responsibility for evaluation of such studies, he failed to include anyone from

the group as an email recipient.

Plaintiff contended, in support of her CEPA claim, that once she learned

of the proposal, she reasonably believed its approval could constitute the sort of

A-5652-18 4 kickback that might run afoul of defendant's CIA and federal law. She testified

at trial that she believed approval of the study, and particularly its expedited

approval, would violate numerous compliance principles, noting that the

proposal had been made by commercial leaders rather than qualified health

economists, that it was not accounted for in defendant's annual budget, and that

it would entail off-label usage. Plaintiff promptly sent an email to her

supervisor, Steven Stein, and to Shaw, complaining that her HEOR group had

not been "kept in the loop" about the proposal, observing that the study seemed

impossible to viably complete prior to the drug's launch, and cautioning that

"[p]er [the] CIA, all customer studies w[ould] have to go through Medical and

HEOR review and approval for medical soundness and methodology rigor, and

we are required to document the review and approval of the study protocol."

Over the next few days, on further review of the proposal, plaintiff sent another

pair of emails to Stein describing what she believed to be several flaws in the

study.

On July 6, 2012, Peter Kwok, an employee in the OSOMM group,

mentioned plaintiff in an email to Grabavoy and expressed concern about her

involvement in the process and the implication for expedited approval:

Can you confirm with Christi that she wants us to move forward with a proposal since [McKesson] is expecting

A-5652-18 5 a quick response from [Novartis]? Or are we going to "wait" for Amy? I think it is unwise to have another "internal review" by Amy and her group; doing so not only means we will likely miss the "deadline" that Christi had originally set for an August completion, it will also send a wrong signal to [McKesson] since they quickly turned this proposal around.

Another email from Kwok to his superiors in the company a few days later added

that this "was not intended to be an HEOR study as we have structured the

deliverables over . . .

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hensley v. Eckerhart
461 U.S. 424 (Supreme Court, 1983)
Rode v. Dellarciprete
892 F.2d 1177 (Third Circuit, 1990)
Verdicchio v. Ricca
843 A.2d 1042 (Supreme Court of New Jersey, 2004)
Donofry v. AUTONOTE SYSTEMS, INC.
795 A.2d 260 (New Jersey Superior Court App Division, 2001)
Maimone v. City of Atlantic City
903 A.2d 1055 (Supreme Court of New Jersey, 2006)
Plainfield-Union Water Co. v. Borough of Mountainside
102 A.2d 1 (Supreme Court of New Jersey, 1954)
Viscik v. Fowler Equipment Co., Inc.
800 A.2d 826 (Supreme Court of New Jersey, 2002)
Rendine v. Pantzer
648 A.2d 223 (New Jersey Superior Court App Division, 1994)
Toto v. Sheriff's Officer Ensuar
952 A.2d 463 (Supreme Court of New Jersey, 2008)
Frugis v. Bracigliano
827 A.2d 1040 (Supreme Court of New Jersey, 2003)
Cavuoti v. New Jersey Transit Corp.
735 A.2d 548 (Supreme Court of New Jersey, 1999)
Desai v. BOARD OF ADJ. OF PHILLIPSBURG
824 A.2d 166 (New Jersey Superior Court App Division, 2003)
Saint Barnabas Medical Center v. County of Essex
543 A.2d 34 (Supreme Court of New Jersey, 1988)
Kolb v. Burns
727 A.2d 525 (New Jersey Superior Court App Division, 1999)
Weichert Co. Realtors v. Ryan
608 A.2d 280 (Supreme Court of New Jersey, 1992)
Beasley v. Passaic County
873 A.2d 673 (New Jersey Superior Court App Division, 2005)
Kas Oriental Rugs, Inc. v. Ellman
926 A.2d 387 (New Jersey Superior Court App Division, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
MIN AMY GUO v. NOVARTIS PHARMACEUTICALS CORPORATION (L-1486-14, MORRIS COUNTY AND STATEWIDE), Counsel Stack Legal Research, https://law.counselstack.com/opinion/min-amy-guo-v-novartis-pharmaceuticals-corporation-l-1486-14-morris-njsuperctappdiv-2022.